AstraZeneca to shutter Indian R&D site
This article was originally published in Scrip
Executive Summary
AstraZeneca is shuttering its Indian R&D site, Avishkar, in Bangalore as part of efforts to "simplify" its research footprint and focus on just its core areas – the oncology, cardio-metabolism and the respiratory, inflammation and autoimmune segments.